FibroGen to Report Third Quarter 2023 Financial Results
October 23 2023 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023
financial results on Monday, November 6 after the market close.
FibroGen will also conduct a conference call on that day at 5:00 PM
Eastern Time with the investment community to further detail the
company's corporate and financial performance.
Conference Call and Audio Webcast Interested
parties may access a live audio webcast of the conference call via
the “Investor Relations” page of the Company’s website at
www.fibrogen.com. To access the call by phone, please go to this
link (registration link), and you will be provided with dial-in
details. To avoid delays, we encourage participants to dial in to
the conference call fifteen minutes ahead of the scheduled start
time. A replay of the webcast will also be available for a limited
time at the following link (webcast replay).
About FibroGen FibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing, and
commercializing a pipeline of first-in-class therapeutics. The
Company applies its pioneering expertise in connective tissue
growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to
advance innovative medicines for the treatment of unmet needs.
Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical
development for the treatment of locally advanced unresectable
pancreatic cancer (LAPC) and metastatic pancreatic cancer.
Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe,
Japan, and numerous other countries for the treatment of anemia in
CKD patients on dialysis and not on dialysis. Roxadustat is in
clinical development for chemotherapy-induced anemia (CIA) in
China. FibroGen recently expanded its research and development
portfolio to include product candidates in the oncology space. For
more information, please visit www.fibrogen.com.
Contacts: FibroGen, Inc.
Investors:David DeLucia, CFAVice President,
Corporate FP&A / Investor Relationsddelucia@fibrogen.com
Media:Meichiel Jennifer KeenanInvestor
Relations and Corporate Communicationsmkeenan@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024